- Home
- STEX vs FENC Comparison
STEX vs FENC Comparison
Compare STEX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEX | FENC |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.8M | 266.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | STEX | FENC |
|---|---|---|
| Price | $1.09 | $6.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 1.9M | 220.8K |
| Earning Date | 05-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | $1,044.81 | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $5.51 |
| 52 Week High | $7.44 | $9.92 |
Technical Indicators
Market Signals| Indicator | STEX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 35.25 | 50.60 |
| Support Level | $0.98 | $5.65 |
| Resistance Level | $3.68 | $8.09 |
| Average True Range (ATR) | 0.12 | 0.38 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 35.00 | 86.27 |
Price Performance
Historical ComparisonAbout STEX Streamex Corp.
Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.